论文部分内容阅读
Aztreonam是第一个单环β-内酰胺类抗生素。曾报道采用8小时投药间隔治疗革兰氏阴性菌感染是安全有效的。然而其消除半衰期约为2小时,对大多数感染的给药间隔可以为12小时。而且Aztreonam的药代动力学特点说明,对于敏感革兰氏阴性菌引起的中至重度感染采用静注1克每12小时1次应当有效。作者采用了多中心、非盲、无对照的方法研究了Aztreonam每日2克治疗中至重度革兰氏阴性杆菌感染,结果如下: 总共176例。其中153例做了评价,男女比率是79∶74;平均年龄为58.6岁,其中38例
Aztreonam is the first monocyclic beta-lactam antibiotic. It has been reported that it is safe and effective to treat Gram-negative bacterial infections with an 8-hour dosing interval. However, its elimination half-life is about 2 hours, and most infections can be administered for 12 hours. Moreover, the pharmacokinetic profile of Aztreonam suggests that an intravenous infusion of 1 g every 12 hours should be effective for moderate to severe infections caused by sensitive Gram-negative bacteria. The authors used a multicenter, unblinded, and uncontrolled approach to study Aztreonam’s treatment of 2 gram daily of moderate-to-severe Gram-negative bacilli with the following results: A total of 176 patients. 153 cases were evaluated, the male-female ratio was 79:74; the average age was 58.6 years, of which 38 cases